Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Initiates Phase 2 Safety and Immunogenicity Trial to Evaluate Annual Re-Dosing of the RSV F Vaccine in Older Adults
- RSV
Oct 22, 2015
Novavax Announces Management Promotion
- Corporate and Finance
Oct 1, 2015
Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization
- RSV
Sep 29, 2015
Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization
- RSV
Sep 29, 2015
Novavax to Host 3rd Annual Analyst and Investor Meeting
- Corporate and Finance
Sep 29, 2015
Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics
- RSV
Sep 29, 2015
Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference
- Corporate and Finance
Sep 21, 2015
Novavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model
- RSV
Sep 15, 2015
Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease
- RSV
Sep 10, 2015
Novavax to Participate in Multiple Investor Conferences in September
- Corporate and Finance
Sep 2, 2015

Show per page